Compare Logitech International SA (LOGI) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Logitech International SA vs ResMed Inc. — how do they compare? Logitech International SA trades at $98.2 (market cap $14.46B), while ResMed Inc. trades at $230.5 (market cap $31.89B). The key difference: ResMed Inc. is far larger — about 2.2× Logitech International SA's market cap, and Logitech International SA pays the higher dividend (1.63%). Which is the better fit depends on your goals — on Pluang, investors hold Logitech International SA for 92 Days and ResMed Inc. for 51 Days on average.
| LOGI | RMD | |
|---|---|---|
Market Cap | $14.46B | $31.89B |
Volume | 349,547 | 618,314 |
Sector | Technology | Health |
52-Week High | $126.69 | $277.88 |
52-Week Low | $85.84 | $182.82 |
Typical Hold Time | 92 Days | 51 Days |
Enterprise Value | $12.79B | $31.24B |
Dividend Yield | 1.63% | 1.16% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Logitech (LOGI) trades at $98.49, down 3.61% on the day, with a neutral technical outlook and mixed analyst sentiment. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Strong profitability is evident with a net income margin of 16.28% and ROE of 35.29%. Recent news highlights product launches and partnerships, including new headsets and a collaboration with SEGA.
The outlook is balanced, with potential upside to the consensus price target of $107.00, supported by solid fundamentals and innovation. Risks include competitive pressures and macroeconomic sensitivity. Analyst consensus is divided, with 26.32% buy ratings, reflecting cautious optimism amid near-term volatility.
ResMed (RMD) trades at $230.91, up 2.18% today, with a bullish technical signal and strong fundamentals. The company reported consistent earnings beats in recent quarters, with Q3 2026 EPS expected at $2.68. Revenue grew to $5.15B in 2025, with a net income margin of 26.94%. Analyst consensus is a buy, with a $242.70 price target. Recent news highlights EPS growth targets of 12%-14% and participation in investor conferences.
Outlook is positive due to robust earnings growth and market share gains, but risks include competitive pressures and regulatory investigations. The stock offers upside to the consensus target, supported by institutional buying and solid cash flow generation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Logitech International SA
Logitech International SA is a Switzerland-based provider of personal computer and mobile accessories for navigation, video communication, and collaboration, smart home, and other applications. Its product portfolio includes mice, keyboards, charging stands, tablet cases, car mounts for mobile devices, remotes, home cameras, home switches, controllers, bluetooth speakers, surround sound, webcams, and conference cameras. It operates in a single segment namely, Peripherals. The firm generates revenue from the Americas, EMEA (Europe, Middle East, Africa), and the Asia Pacific region.
Read more on LOGI →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
